RxDoctor Payments Data

Claudiu-Gily Ionescu-Tajti, MD

Internal Medicine · Lyme, NHNPI 1265559553

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 24 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by AbbVie at 39.4% of the total. Reporting peaked in 2024 at $150 and has fallen 90.0% since, to $15 in 2025.

$517in general payments, 2019–2025

Across 24 payments — averaging $21.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$203
  • Sanofi-aventis U.S. LLC$48
  • Boehringer Ingelheim$30
  • Otsuka America Pharmaceutical, Inc.$28
  • Astellas Pharma US Inc$27
  • Novartis$24
  • plus $155 from 8 others

What the payments were for

  • Food & beverage$517100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$517 in reported general payments places this provider in the 85th percentile of 504 internal medicine providers in New Hampshire.

See all internal medicine providers in New Hampshire

Medicare billing

Part B allowed, 2024
$42,832
Medicare patients
202
Services billed
8,077

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban149$142,202
TrulicityDulaglutide41$49,013
OzempicSemaglutide36$43,863
XareltoRivaroxaban46$41,091
MounjaroTirzepatide39$39,451
Teriparatide16$33,292
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$28,873
JardianceEmpagliflozin18$25,341
RybelsusSemaglutide22$21,227
Arnuity ElliptaFluticasone Furoate29$12,131
Spiriva HandihalerTiotropium Bromide20$10,422
Incruse ElliptaUmeclidinium Bromide18$8,780
SymbicortBudesonide/Formoterol Fumarate17$4,161
Potassium Chloride159$4,139
Varenicline Tartrate22$4,008

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$18$142,202149 claims
Lilly USA, LLCTrulicity, Mounjaro$15$88,46480 claims
GSKTrelegy Ellipta, Arnuity Ellipta, Incruse Ellipta$24$49,78477 claims
Boehringer IngelheimJardiance$30$25,34118 claims
AstraZenecaSymbicort$14$4,16117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 504 internal medicine providers in New Hampshire.

Other internal medicine in Lyme

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →